Drug Information

Drug General Information
Drug ID
D04MXN
Former ID
DIB002218
Drug Name
CEP-32496
Synonyms
AB-024; B-RAF kinase inhibitors (melanoma), Ambit/Cephalon
Drug Type
Small molecular drug
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 1/2 [524329], [542805]
Company
Teva pharmaceutical
Structure
Download
2D MOL

3D MOL
Formula
C24H22F3N5O5
InChI
InChI=1S/C24H22F3N5O5/c1-23(2,24(25,26)27)19-11-20(32-37-19)31-22(33)30-13-6-5-7-14(8-13)36-21-15-9-17(34-3)18(35-4)10-16(15)28-12-29-21/h5-12H,1-4H3,(H2,30,31,32,33)
InChIKey
DKNUPRMJNUQNHR-UHFFFAOYSA-N
PubChem Compound ID
56846693
PubChem Substance ID
138480059, 160683809, 160862042, 163370756, 163620836, 163686164, 185997028, 198942057, 218199956, 223348379, 223366209, 225979552, 227268997, 251963033, 252471028
Target and Pathway
Target(s) B-Raf proto-oncogene serine/threonine-protein kinase Target Info Inhibitor [550245]
KEGG Pathway MAPK signaling pathway
ErbB signaling pathway
Rap1 signaling pathway
cAMP signaling pathway
Chemokine signaling pathway
FoxO signaling pathway
mTOR signaling pathway
Vascular smooth muscle contraction
Focal adhesion
Natural killer cell mediated cytotoxicity
Long-term potentiation
Neurotrophin signaling pathway
Serotonergic synapse
Long-term depression
Regulation of actin cytoskeleton
Insulin signaling pathway
Progesterone-mediated oocyte maturation
Alcoholism
Hepatitis C
Pathways in cancer
Proteoglycans in cancer
Colorectal cancer
Renal cell carcinoma
Pancreatic cancer
Endometrial cancer
Glioma
Prostate cancer
Thyroid cancer
Melanoma
Bladder cancer
Chronic myeloid leukemia
Acute myeloid leukemia
Non-small cell lung cancer
NetPath Pathway IL-7 Signaling Pathway
PANTHER Pathway Angiogenesis
Integrin signalling pathway
Interleukin signaling pathway
PDGF signaling pathway
T cell activation
VEGF signaling pathway
Ras Pathway
CCKR signaling map ST
Pathway Interaction Database CDC42 signaling events
mTOR signaling pathway
Ras signaling in the CD4+ TCR pathway
ErbB1 downstream signaling
PDGFR-beta signaling pathway
Signaling events mediated by VEGFR1 and VEGFR2
Trk receptor signaling mediated by the MAPK pathway
PathWhiz Pathway Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
Intracellular Signalling Through Adenosine Receptor A2b and Adenosine
Reactome Spry regulation of FGF signaling
Frs2-mediated activation
ARMS-mediated activation
CREB phosphorylation through the activation of Ras
RAF activation
MAP2K and MAPK activation
Negative feedback regulation of MAPK pathway
Negative regulation of MAPK pathway
WikiPathways Serotonin Receptor 4/6/7 and NR3C Signaling
Serotonin HTR1 Group and FOS Pathway
Estrogen signaling pathway
Senescence and Autophagy in Cancer
Regulation of Actin Cytoskeleton
EGF/EGFR Signaling Pathway
MAPK Cascade
MAPK Signaling Pathway
Focal Adhesion
Bladder Cancer
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
Polycystic Kidney Disease Pathway
Corticotropin-releasing hormone
B Cell Receptor Signaling Pathway
Signaling Pathways in Glioblastoma
TSH signaling pathway
Integrated Breast Cancer Pathway
Signaling by FGFR
NGF signalling via TRKA from the plasma membrane
Integrin-mediated Cell Adhesion
References
Ref 524329ClinicalTrials.gov (NCT01877811) CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2. U.S. National Institutes of Health.
Ref 542805(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7880).
Ref 550245Clinical pipeline report, company report or official report of Ambit Biosciences.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.